BARRY M. BERNSTEIN,RAJEEV M. MENON,AMIT KHATRI,SVEN MENSING,SANDEEP DUTTA,DANIEL E. COHEN,THOMAS J. PODSADECKI,SCOTT C. BRUN,WALID M. AWNI,EMILY O. DUMAS,CHERI E. KLEIN
申请号：
SE1450019
公开号：
SE1450019A1
申请日:
2012.10.19
申请国别(地区):
SE
年份:
2014
代理人:
摘要：
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
